Vantive to divest majority of its hemodialysis assets to Rockwell Medical
Vantive entered a definitive agreement to sell most of its hemodialysis business—including concentrates, monitors, water‑treatment systems and related consumables—to Rockwell Medical. The transaction does not include Vantive’s Theranova dialyzer line and is slated to close in mid‑2027, subject to regulatory approvals. Both CEOs said the deal will let Vantive focus on home dialysis and critical‑care therapies while giving Rockwell a larger product portfolio. Financial terms differ across reports, with values ranging from $1.2 billion to $1.5 billion, and one source citing a $125 million price.
Why it matters
The divestiture sharpens Vantive’s strategic focus on home dialysis and ICU care, potentially improving its growth prospects in those segments. Rockwell Medical will expand its hemodialysis offerings and gain a manufacturing campus in Italy, which could boost its revenue to $400‑$450 million annually, according to the deal description.
Key facts
- 1Vantive agreed to sell the majority of its hemodialysis assets to Rockwell Medical. stocktitan.net
- 2The assets include hemodialysis concentrates, HD monitors, water‑treatment systems and related consumables. prnewswire.com
- 3Vantive’s Theranova dialyzer portfolio is excluded from the transaction. prnewswire.com
- 4The deal is expected to close in mid‑2027, pending regulatory approvals and customary closing conditions. prnewswire.com
- 5One press release states the purchase price as $1.2 billion. prnewswire.com
- 6Another source reports a price of $1.5 billion. stocktitan.net
Open questions
- Conflicting purchase price figures: $1.2 billion (source 2), $1.5 billion (source 1), and $125 million (source 4).
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.